Research programme: immuno-oncology therapeutics - Batu Biologics

Drug Profile

Research programme: immuno-oncology therapeutics - Batu Biologics

Alternative Names: Cancer vaccine - Batu Biologics; DendroVax™; hp91; Immittam™; ImmStem™; ImmXcyte™; Stem cell therapy - Batu Biologics; ValloVax™

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Batu Biologics
  • Class Cancer vaccines; Dendritic cell vaccines; Stem cell therapies
  • Mechanism of Action Angiogenesis inhibitors; Cell replacements; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma; Non-small cell lung cancer; Solid tumours
  • Discontinued Septic shock

Most Recent Events

  • 08 Nov 2017 USFDA approves IND application for ValloVax™ in Non-small cell lung cancer
  • 07 Nov 2017 Batu Biologics plans a phase I trial for Non-small stage lung cancer in USA
  • 08 Sep 2017 Discontinued - Preclinical for Septic shock in USA (Parenteral) (Batu Biologics pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top